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Abstract
A Phase 2 dose-finding study evaluated isatuximab, an anti-CD38 monoclonal antibody, in relapsed/refractory
multiple myeloma (RRMM; NCT01084252). Patients with ≥3 prior lines or refractory to both immunomodulatory
drugs and proteasome inhibitors (dual refractory) were randomized to isatuximab 3 mg/kg every 2 weeks (Q2W),
10 mg/kg Q2W(2 cycles)/Q4W, or 10 mg/kg Q2W. A fourth arm evaluated 20 mg/kg QW(1 cycle)/Q2W. Patients
(N= 97) had a median (range) age of 62 years (38–85), 5 (2–14) prior therapy lines, and 85% were double refractory.
The overall response rate (ORR) was 4.3, 20.0, 29.2, and 24.0% with isatuximab 3 mg/kg Q2W, 10 mg/kg Q2W/Q4W,
10 mg/kg Q2W, and 20 mg/kg QW/Q2W, respectively. At doses ≥10 mg/kg, median progression-free survival and
overall survival were 4.6 and 18.7 months, respectively, and the ORR was 40.9% (9/22) in patients with high-risk
cytogenetics. CD38 receptor density was similar in responders and non-responders. The most common non-
hematologic adverse events (typically grade ≤2) were nausea (34.0%), fatigue (32.0%), and upper respiratory tract
infections (28.9%). Infusion reactions (typically with first infusion and grade ≤2) occurred in 51.5% of patients. In
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The introduction of proteasome inhibitors (PIs) and
immunomodulatory agents (IMiDs) has improved clinical
outcomes in patients with multiple myeloma (MM) [1], and
5-year survival rates have increased steadily to reach 52%
for the 2009–2015 period [2]. However, survival declines
with successive lines of therapy [3], and only a third of
patients diagnosed with MM are expected to survive beyond
10 years [4]. Patients with MM that is dual refractory to
IMiDs (thalidomide or lenalidomide) and PIs (bortezomib
or carfilzomib) have a median overall survival (OS) of only
13 months [5]. Although patients with relapsed/refractory
MM (RRMM) commonly receive triplet/combination ther-
apy [6, 7], novel agents such as daratumumab, a CD38-
targeting IgG1Κ human monoclonal antibody, and carfil-
zomib have demonstrated efficacy as monotherapy in these
patients and are approved for such use in the United States
[8, 9]. Additional agents with single agent activity and the
potential for augmented efficacy in combination regimens
are needed to improve outcomes in patients with RRMM.
CD38 is a transmembrane glycoprotein that has multiple
functions as both a receptor and an enzyme. It is uniformly,
and often highly, expressed on malignant plasma cells, making
it an attractive target for the treatment of MM [10, 11]. Isa-
tuximab is an IgG1-kappa monoclonal antibody that binds
CD38 via a specific epitope distinct from that of daratumumab
[12]. Isatuximab induces tumor cell death via multiple
mechanisms, including antibody-dependent cellular cytotoxi-
city (ADCC), antibody-dependent cellular phagocytosis,
complement-dependent cytotoxicity (CDC), and direct apop-
tosis, and may also activate an immune response against tumor
cells through regulation of the tumor immunosuppressive
environment via modulation of adenosine levels [12–14].
In a Phase 1 dose escalation study of single agent isa-
tuximab in patients with RRMM who had previously
received an IMiD and a PI, the overall response rate (ORR)
was 24% (15/63 patients) at doses 10–20 mg/kg, including
one complete response (CR) [15]. We report results from
part 1 of a Phase 2 study that evaluated the safety and
efficacy of isatuximab monotherapy to select the optimal
dose and schedule in heavily pretreated patients for use in
part 2; results from part 2 evaluating the efficacy of isa-
tuximab alone and in combination with dexamethasone at
the dose selected from part 1 will be reported separately.
Subjects and methods
Study design
This Phase 2, open-label, randomized, international, multi-
center study (NCT01084252) was conducted across 17 study
centers (14 in the USA, 2 in Spain, and 1 in Greece). The
protocol was approved by institutional review boards/ethics
committees and patients provided written informed consent
to participate. The study was conducted according to the
Declaration of Helsinki and the International Council for
Harmonisation of Technical Requirements for Pharmaceu-
ticals for Human Use Good Clinical Practice.
Study population
Adult patients (≥18 years) with MM were eligible to parti-
cipate if their disease was refractory to both an IMiD and a
PI, or if they had received three or more prior lines of
therapy that included an IMiD and PI. All patients must also
have received an alkylating agent, have had measurable
disease, and obtained a minimal response or better to at least
one prior line of therapy, according to International Mye-
loma Working Group (IMWG) Uniform Response Criteria
[16]. Other key inclusion criteria included an Eastern
Cooperative Group performance status ≤2 or Karnofsky
performance status ≥60 and creatinine clearance
≥30 ml/min. Patients with a stem cell transplant more than
12 weeks prior to starting study treatment were eligible to
participate. Patients with IgM myeloma, amyloidosis,
myelodysplastic syndrome, or plasma cell leukemia were
excluded. Previous anti-CD38 therapy was not permitted,
and no other anticancer medications were allowed during
the study.
Treatment
Patients were randomized in a 1:1:1 ratio to one of three
dosing regimens, all administered in 28-day cycles. Arm 1
received isatuximab 3 mg/kg every 2 weeks (Q2W), Arm 2
received isatuximab 10 mg/kg Q2W, and Arm 3 received
isatuximab 10 mg/kg Q2W for two cycles followed by 10
mg/kg every 4 weeks (Q4W; Day 1 of each cycle only).
Randomization was carried out via an Interactive Voice
Response System/Interactive Web Response System and
was stratified by prior treatment with pomalidomide and/or
carfilzomib. As a protocol amendment, based on pharma-
cokinetic (PK) analysis of Phase 1 data, a fourth arm was
added for which patients received isatuximab 20 mg/kg
once a week (QW) during the first 28-day cycle and Q2W
thereafter. Intrapatient dose escalation (not to exceed 20 mg/
kg on the Q2W schedule) was permitted at the discretion of
the study sponsor and treating physician for patients with
progressive disease if the original dose regimen was toler-
ated for at least one cycle.
Isatuximab was administered at an initial infusion rate of
175 mg/h, which could be increased in the absence of
infusion reactions (IRs) up to a maximum of 400 mg/h.
Prophylaxis was given 15–30 min prior to isatuximab
J. Mikhael et al.
infusion to reduce the risk and severity of IRs, consisting
of diphenhydramine 25–50 mg IV, methylprednisolone
100 mg IV, ranitidine 50 mg IV (or equivalents for each),
and acetaminophen (paracetamol) 650–1000 mg PO.
Patients continued treatment until disease progression,
unacceptable toxicity, or another reason for discontinuation.
At the end of treatment, those with disease progression were
followed every 3 months until death or study cut-off date
and those without disease progression were followed
monthly until disease progression, initiation of another
anticancer therapy, death, or study cut-off date.
Outcomes
The primary efficacy endpoint was ORR, which included
stringent CR, CR, very good partial response (VGPR), or
partial response (PR). Responses were assessed by the Inde-
pendent Adjudication Committee (IAC) using the IMWG
Uniform Response Criteria [16], and were determined from
central laboratory M-protein (serum and 24-h urine), serum
free light chain and serum β2-microglobulin measurements,
bone marrow biopsy/aspiration, radiologic imaging of plas-
macytoma, and bone skeletal survey. Secondary efficacy
endpoints included duration of response, clinical benefit rate,
progression-free survival (PFS), and OS. Subgroup analyses
were performed for characteristics of interest: age, sex,
International Staging System stage, transplant history, high-
risk cytogenetics (del[17p] or t[4:14]), renal function, and
prior therapies. Patients were termed double refractory if they
were refractory to both an IMiD and PI, and quadruple
refractory if they were refractory to lenalidomide, pomalido-
mide, bortezomib, and carfilzomib.
Exploratory endpoints included analysis of Fc gamma
receptor polymorphism from baseline blood samples and
CD38 receptor density from baseline bone marrow aspirates
to evaluate correlations with clinical response.
Disease assessment was on Day 1 of Cycle 2, and Day 1
of every subsequent cycle thereafter. Safety was evaluated
based on physical examination, laboratory tests, and
adverse event (AE) reporting, which was graded by the
National Cancer Institute Common Terminology Criteria
for Adverse Events v4.03. High-risk cytogenetics, defined
as t(4:14) and/or del(17p), were assessed at a central
laboratory using fluorescent in situ hybridization, or local
assessment when central data were not available. Blood
concentrations of isatuximab were analyzed for population
PK using non-linear mixed effects modeling.
Statistical analyses
A selection design was used to maximize the probability of
selecting the best of four isatuximab doses using ORR as
the endpoint [17]. Target enrollment was 96 patients (24
patients per arm) to give at least an 80% probability of
selecting the best dose assuming an ORR of 10% with 3 mg/
kg and a difference in ORR of at least 15% between the best
dose and the 3 mg/kg arm.
Analyses of efficacy and safety were based on the all
treated population, which comprised all patients who
received at least one full or partial administration of isa-
tuximab. For the primary endpoint of ORR, results are
summarized as descriptive statistics.
Duration of response, OS, and PFS were analyzed using
the Kaplan–Meier method with estimated median and 95%
confidence interval (CI). The exploratory analysis of Fc
gamma receptor polymorphism used logistic regression




The study started on July 2, 2014, with a part 1 data cut-off
of December 9, 2016; 12 months after the first dose of the
last patient. A total of 97 patients were treated with isa-
tuximab in the dose-finding section of the study.
Patient demographics, disease characteristics, and treat-
ment history are presented by dose group in Table 1. There
were no notable imbalances in patient characteristics across
the treatment arms. The median age of patients was 62 years
(range 38–85) and median time since diagnosis was 5.8
years (range 1.2–24.1). Overall at baseline, 36/97 (37.1%)
patients had International Staging System III disease, 33/97
patients (34.0%) had creatinine clearance <60 ml/min, and
28/97 (28.9%) patients had at least one high-risk cytoge-
netic abnormality (17 with del[17p] and 15 with t[4:14]).
The study population had been heavily pretreated, with a
median of five prior lines of therapy (range, 2–14). In total,
82/97 (84.5%) patients were double refractory and 32/97
patients (33.0%) were quadruple refractory.
Patient disposition is shown in Fig. 1. In the overall
population, patients received a median 3 cycles (range
1–19) and the median duration of treatment was 13 weeks
(range 2–77). In the dose groups ≥10 mg/kg, the median
number of cycles was 4 and median duration of exposure
was between 14.0 and 15.9 weeks across the three cohorts.
The median duration of isatuximab infusion was reduced
between the first infusion and subsequent infusions, from
3.2 to 2.6 h for 10 mg/kg, and 5.3 to 4.4 h for 20 mg/kg.
Efficacy
The ORR by IAC assessment for all dose groups was 19.6%
(19/97 patients), including 11.3% (11/97 patients) with a
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Table 1 Patient demographics, disease characteristics, and treatment history (all treated population, N= 97).











Age in years, median (range) 63 (44–80) 59 (49–81) 66 (38–83) 59 (48–85) 62 (38–85)
Male, n (%) 12 (52.2) 18 (72.0) 13 (54.2) 12 (48.0) 55 (56.7)
Race, n (%)
White 21 (91.3) 19 (76.0) 19 (79.2) 21 (84.0) 80 (82.5)
Black or African American 1 (4.3) 4 (16.0) 2 (8.3) 3 (12.0) 10 (10.3)
Asian 0 0 0 1 (4.0) 1 (1.0)
Other 1 (4.3) 2 (8.3) 3 (12.5) 0 6 (6.2)
Ethnicity, n (%)a
Hispanic or Latino 0 1 (4.0) 2 (8.3) 2 (8.0) 5 (5.2)
Not Hispanic or Latino 22 (95.7) 23 (9.0) 22 (91.7) 23 (92.0) 90 (92.8)
ECOG score (Karnofsky PS), n (%)
0 (100%) 7 (30.4) 1 (4.0) 0 8 (32.0) 16 (16.5)
1 (80–90%) 11 (47.8) 22 (88.0) 22 (91.7) 14 (56.0) 69 (71.1)
2 (60–70%) 5 (21.7) 2 (8.0) 2 (8.3) 3 (12.0) 12 (12.4)
Creatinine clearance <60 ml/min, n (%) 9 (39.1) 8 (32.0) 10 (41.7) 6 (24.0) 33 (34.0)
Years since initial diagnosis, median (range) 5.8 (2.2–11.0) 5.5 (1.2–12.7) 7.1 (3.4–24.1) 6.1 (1.8–14.3) 5.8 (1.2–24.1)
Measurable paraprotein, n (%)b
Serum M-protein 17 (73.9) 20 (80.0) 17 (70.8) 17 (68.0) 71 (73.2)
Urine M-protein 1 (4.3) 4 (16.0) 5 (20.8) 5 (20.0) 15 (15.5)
κ light chain 3 (13.0) 0 1 (4.2) 3 (12.0) 7 (7.2)
λ light chain 1 (4.3) 1 (4.0) 1 (4.2) 0 3 (3.1)
ISS stage at baseline, n (%)b
I 5 (21.7) 8 (32.0) 6 (25.0) 11 (44.0) 30 (30.9)
II 8 (34.8) 5 (20.0) 10 (41.7) 7 (28.0) 30 (30.9)
III 9 (39.1) 12 (48.0) 8 (33.3) 7 (28.0) 36 (37.1)
Bone marrow plasma cells, median % (range) 45.0 (1.4–95.0) 24.6 (1.0–97.0) 17.0 (0.0–81.8) 25.5 (1.4–90.0) 24.6 (0.0–97.0)
Extramedullary plasmacytoma at baseline, n (%) 4 (17.4) 7 (28.0) 4 (16.7) 2 (8.0) 17 (17.5)
High-risk cytogeneticsc, n (%) 6 (26.1) 5 (20.0) 7 (29.2) 10 (40.0) 28 (28.9)
del(17p) 2 (8.7) 3 (12.0) 5 (20.8) 7 (28.0) 17 (17.5)
t(4:14) 5 (21.7) 2 (8.0) 3 (12.5) 5 (20.0) 15 (15.5)
Median prior lines of therapy, n (range) 5 (2–12) 5 (3–14) 6 (2–13) 5 (2–10) 5 (2–14)
≥1 prior stem cell transplant, n (%) 20 (87.0) 23 (92.0) 21 (87.5) 22 (88.0) 86 (88.7)
Refractory to an immunomodulatory drug, n (%)d 21 (91.3) 23 (92.0) 22 (91.7) 23 (92.0) 89 (91.8)
Refractory to lenalidomide, n (%) 19 (82.6) 20 (80.0) 20 (83.3) 22 (88.0) 81 (83.5)
Refractory to pomalidomide, n (%) 17 (73.9) 16 (64.0) 16 (66.7) 13 (52.0) 62 (63.9)
Refractory to a proteasome inhibitor, n (%)d 19 (82.6) 23 (92.0) 22 (91.7) 23 (92.0) 87 (89.7)
Refractory to bortezomib, n (%) 17 (73.9) 22 (88.0) 16 (66.7) 17 (68.0) 72 (74.2)
Refractory to carfilzomib, n (%) 12 (52.2) 17 (68.0) 14 (58.3) 16 (64.0) 59 (60.8)
Refractory to alkylating agent, n (%) 15 (65.2) 15 (60.0) 17 (70.8) 14 (56.0) 61 (62.9)
Double refractory, n (%)e 18 (78.3) 22 (88.0) 20 (83.3) 22 (88.0) 82 (84.5)
Refractory to pomalidomide and carfilzomib 11 (47.8) 14 (56.0) 12 (50.0) 9 (36.0) 46 (47.4)
Quadruple refractory, n (%)f 9 (39.1) 11 (44.0) 7 (29.2) 5 (20.0) 32 (33.0)
ECOG Eastern Cooperative Oncology Group, ISS International Staging System, PS performance status, QnW once every n weeks.
aData missing for one patient each in the 3 mg/kg Q2W and 10 mg/kg Q2W/Q4W arms.
bData missing for one patient in the 3 mg/kg Q2W arm.
cHigh-risk cytogenetics defined as t(4:14) translocation and/or 17p deletion. Cytogenetic status unknown for t(4:14) in 19 patients (4 patients in 3
mg/kg Q2W arm, 7 patients in 10 mg/kg Q2W/Q4W, 6 patients in 10 mg/kg Q2W, and 2 patients in 20 mg/kg QW/Q2W arms; and for del(17p) in
19 patients (3 patients in 3 mg/kg Q2W arm, 8 patients in 10 mg/kg Q2W/Q4W, 6 patients in 10 mg/kg Q2W, and 2 patients in 20 mg/kg QW/
Q2W arms).
dRefractory disease defined according to International Myeloma Working Group criteria.
eDouble refractory was defined as refractory to an immunomodulatory agent and a proteasome inhibitor.
fQuadruple refractory was defined as refractory to lenalidomide, bortezomib, pomalidomide, and carfilzomib.
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VGPR and 8.2% (8/97) with a PR; no CR were observed.
The ORR based on investigator assessment was similar at
21.6% (21/97 patients). The ORR by dose (Supplementary
Fig. 1a) was 4.3% in the isatuximab 3 mg/kg arm arising
from one PR, 20.0% (5/25 patients) at 10 mg/kg Q2W/
Q4W, 29.2% (7/24) at 10 mg/kg Q2W, and 24.0% (6/25) at
20 mg/kg QW/Q2W. At doses ≥10 mg/kg, the ORR was
24.3% (18/74 patients), which included 14.9% (11/74) of
patients with a VGPR and 9.5% (7/74) with a PR. The
overall clinical benefit rate was 28.9% (28/97 patients) by
IAC and 30.9% (30/97 patients) by investigator assessment.
By dose group, the clinical benefit rate was 4.3% (1/23
patients) for 3 mg/kg Q2W, 41.7% (10/24) for 10 mg/kg
Q2W, 32.0% (8/25) for 10 mg/kg Q2W/Q4W, and 36.0%
(9/25) for 20 mg/kg QW/Q2W.
The ORR at doses ≥10 mg/kg was maintained in sub-
group analyses of patients with baseline characteristics
indicative of a poor prognosis (Supplementary Fig. 1b).
Notably, at doses ≥10 mg/kg, the ORR was 46.2% (6/13) vs
19.7% (12/61) in patients aged ≥70 years vs <70 years, and
40.9% (9/22) vs 17.3% (9/52) in patients with vs without
high-risk cytogenetic markers, respectively. By cytogenetic
abnormality, the ORR was 40.0% (6/15 patients) for
del(17p) and 40.0% (4/10 patients) for t(4:14). Furthermore,
at doses ≥10 mg/kg, the ORR varied little by prior treatment
history, with 23.3% (14/60) of patients with three or more
previous lines of therapy, 25.0% (16/64) of patients with
double refractory disease, and 17.4% (4/23) of patients with
quadruple refractory disease achieving at least a PR.
Patients responded early to treatment and these responses
were durable (Supplementary Fig. 2). Median time to first
response was 1.8 months (range 0.9–5.7). The duration of
response was 1.9 months in the one responder in the 3 mg/
kg arm, 8.3 months (3.7–12.4) in the 10 mg/kg Q2W/Q4W
group, 14.8 months (3.7–16.6) in the 10 mg/kg Q2W group,
and 8.3 months (3.7–10.2) in the 20 mg/kg QW/
Q2W group.
Median PFS ranged from 2.1 months in the 3 mg/kg
Q2W arm to 9.6 months in the 10 mg/kg Q2W arm
(Fig. 2a). Median OS was 15.3 months in the 3 mg/kg Q2W
group, 18.6 months in the 10 mg/kg Q2W group, and not
reached in the 10 mg/kg Q2W/Q4W and 20 mg/kg QW/
Q2W groups (Fig. 2b). At doses ≥10 mg/kg, median PFS
was 4.6 months (95% CI, 2.8–9.2) and median OS was
18.7 months (95% CI, 11.7–not reached).
Safety
Almost all patients had at least one treatment-emergent AE
(TEAE; 96/97 [99.0%] patients) and 66/97 (68.0%) patients
had a grade ≥3 TEAE. The most common any grade TEAEs
(≥20% of patients), grade ≥3 TEAEs (≥5% of patients), and
hematologic abnormalities are presented in Table 2. IRs
were the most commonly reported non-hematologic TEAE,
reported in 50/97 (51.5%) patients, and were also the most
frequently reported drug-related TEAE. IRs mostly occur-
red with the first infusion, with 5/97 (5.2%) patients
experiencing IRs during the second infusion or later, and
were mostly grade 1 or 2 in severity, with only two cases of
grade ≥3 IRs. There was no difference in IR incidence
between 10 and 20 mg/kg dose levels (56.0–58.3 vs 56.0%),
however, incidence was lower at 3 mg/kg (34.8%).
Besides IRs, drug-related TEAEs reported in ≥5% of
patients consisted of chills (16.5%), nausea (15.5%), dys-
pnea (12.4%), chest discomfort (11.3%), flushing (11.3%),
cough (8.2%), headache (7.2%), vomiting (6.2%), and
Fig. 1 Study design and treatment disposition. QnW every n week.
*Randomization to Arms 1–3 was stratified according to whether or
not patients had received prior treatment with pomalidomide and/or
carfilzomib. †Analysis of the pharmacokinetic parameters of patients
treated at 10 mg/kg Q2W in the expansion cohort of the Phase 1 study
demonstrated a high level of variability in exposure and non-linear
clearance, suggesting that a higher dose and more intense “loading”
schedule may be required to reach the desired therapeutic concentra-
tion faster. Therefore, Arm 4 was included, which evaluated a dose and
schedule of 20 mg/kg QW for 1 cycle followed by 20 mg/kg Q2W. ‡At
study cut-off, December 9, 2016.
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wheezing (5.2%). Except for dyspnea, which occurred at
grade ≥3 in 1 patient (1.0%), none of these drug-related
TEAEs were reported at grade >2.
The most frequently reported grade ≥3 TEAEs were
hematologic abnormalities and pneumonia (Table 2).
Grade 3 febrile neutropenia occurred in one patient in
the 3 mg/kg Q2W arm, but no neutropenic infections
were observed. Four patients (4.1%) had a serious drug-
related TEAE, comprising one anaphylactic reaction with
bronchospasm and one varicella zoster infection in the
10 mg/kg Q2W group, and one case of gastroenteritis and
one case of meningococcal sepsis in the 20 mg/kg QW/
Q2W group.
Five AEs (5.2%) led to withdrawal from the study, of
which two were IRs: one grade 4 IR (anaphylactic reaction
and bronchospasm), one grade 3 IR, one sudden death (not
considered related to isatuximab), one grade 3 platelet count
decrease, and one grade 5 atrial fibrillation (not considered
related to isatuximab). There were eight (8.2%) deaths
during the treatment period: three due to AEs (cerebral
hemorrhage, atrial fibrillation, and sudden death), and five
due to progressive disease, none of which were considered
related to treatment.
None of the 94 evaluable patients were positive for anti-
drug antibodies at baseline or after isatuximab administration.
Exploratory analyses: CD38 receptor density and Fc
gamma receptor polymorphism
Of the 60 patients evaluable for CD38 receptor density at
baseline, median CD38 receptor density was 151,317
molecules/cell (range 53,307–539,799) in 15 responders
and 143,408 molecules/cell (49,354–349,722) in 45 non-
responders. At active doses ≥10 mg/kg, the ORR for
patients with CD38 receptor density above or below the
threshold value of 150,000 molecules/cell was 33.3% (8/24
patients) and 27.3% (6/22 patients), respectively.
The prevalence of FcγRIIIA (CD16) cytogenetic
variants was 10.7% (10/93 patients) FcγRIIIA V/V, 39.8%
(37/93) F/F, and 49.5% (46/93) F/V. The highest ORR
(60.0%; 6/10 patients) was observed in the V/V variant
population, compared with 8.1% (3/37) for F/F and 19.6%
(9/46) for F/V.
PK
Based on the geometric means ratio, increasing the dose
of isatuximab 6.7-fold from 3 to 20 mg/kg resulted in a
dose-proportional increase in the maximum concentration
(Cmax) at Cycle 1 Day 1 (6.9-fold increase), whereas area
under the curve (AUC) at Week 1 (AUC 1W) increased in
10
Fig. 2 Survival (all treated
population; N = 97).
a Progression-free survival.
b Overall survival.
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a greater than dose-proportional manner (8.5-fold
increase). When the dose was increased 2-fold, from 10 to
20 mg/kg, there was a dose-proportional increase in Cmax
and AUC 1W (both 1.8-fold increase) (Table 3). This
suggests the presence of target-mediated drug disposition
with isatuximab. For the 10 mg/kg Q2W schedule, the
accumulation ratio for Cmax was 1.3 at Cycle 2 and 1.9 at
Cycle 6. For the 10 mg/kg Q2W/Q4W schedule, an
accumulation in Cmax and Ctrough was observed at Cycle 2,
but no longer at Cycle 6 (Ctrough accumulation ratio, 0.68).
For the 20 mg/kg QW/Q2W schedule, accumulation ratios
at Cycle 2 were 2.2 for Cmax and 3.3 for Ctrough, and were
similar at Cycle 6 (2.3 and 3.6, respectively), indicating
that steady state is reached by Cycle 2 for this adminis-
tration schedule (Table 4).
Discussion
In this study in heavily pretreated patients with RRMM,
single agent isatuximab showed promising efficacy at doses
≥10 mg/kg, with 24.3% of patients demonstrating a
response to treatment and 14.9% achieving a VGPR, with a
median PFS of 4.6 months and median OS of 18.7 months.
These responses were durable, lasting from 8.3 to
14.8 months depending on dose schedule, and occurred
early, often at the first disease assessment (median time to
first response, 1.8 months).
The efficacy of isatuximab is important given the prior
treatment burden of patients in this study, comprising a
median five previous lines of therapy and 85% dual
refractoriness to IMiDs and PIs. It is well recognized that
responses diminish with successive treatment regimens [3],
and real-world studies in similar patient populations high-
light the poor prognosis (median OS of 8–13 months) of
these patients [5, 18].
Responses to isatuximab were consistently demonstrated
in all high-risk groups analyzed, including those with more
than three prior lines of therapy, double and quadruple
refractory disease, ≥70 years of age, and at least one high-
risk cytogenetic abnormality. Indeed, the ORR was higher
in older and high-risk cytogenetic patients than the overall
population, although small subgroup numbers warrant
caution when interpreting the data. The efficacy of isatux-
imab in these hard-to-treat patients is promising, especially
given real-world data showing reduced response rates and
OS in older patients compared with their younger counter-
parts [19–21] and reduced median OS in patients with high-
risk cytogenetics vs standard-risk patients [22, 23].
The results of this study with isatuximab monotherapy
compare favorably with those from studies supporting
approved single agents in RRMM. In the Phase 2 SIRIUS
study of daratumumab, patients had received an alkylating
agent and at least three prior lines of therapy, including a PI
and IMiD, or were double refractory to the last PI and IMiD
received. In the daratumumab 16 mg/kg arm (n= 106),
patients had a median five prior lines of therapy (range
2–14) and 95% were double refractory to a PI and IMiD.
The ORR (primary endpoint) was 29.2% (including 3 CRs
and 10 VGPRs, corresponding to 12.3% of patients
achieving ≥VGPR), median PFS was 3.7 months and
median OS was 17.5 months [24]. In a Phase 2 study of
carfilzomib in 266 patients with MM who had received at
Table 3 Geometric means for isatuximab AUC 1W and Cmax across
the dose range investigated.




3 mg/kg Q2W (n= 23) 3023 41
10 mg/kg Q2W (n= 21) 13,837 153
10 mg/kg Q2W/Q4W (n= 25) 13,713 154
10 mg/kg Q2W for C1a (n= 46) 13,769 154
20 mg/kg QW/Q2W (n= 24) 25,596 279
AUC 1W predicted cumulative area under the plasma concentration
curve over the first week (0–168 h), C cycle, C1D1 cycle 1, day 1,
Cmax maximum plasma concentration, QnW every n weeks.
aC1–C2 for Cmax.
Table 4 Exposure (Cmax, Ctrough,
and AUC0−τ) parameters for
isatuximab in a typical patient,
with accumulation ratios.

















10 mg/kg Q2W 142 24.7 18,288 190 66.7 272 132 58,557
Accumulation ratio 1.34 2.70 1.92 5.35 3.20
10 mg/kg Q2W/Q4W 142 24.7 18,288 190 66.7 163.4 16.8 36,090
Accumulation ratio 1.34 2.70 1.15 0.68 –
20 mg/kg QW/Q2W 278 103 26,711 617 335 651 369 152,884
Accumulation ratio 2.22 3.26 2.34 3.60 –
AUC0−τ predicted cumulative area under the plasma concentration curve from time zero to time τ, Cmax
maximum plasma concentration, Ctrough plasma concentration before treatment administration during
repeated dosing, QnW every n week.
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least two prior therapies, including bortezomib and an
IMiD, the ORR (primary endpoint) was 23.7%, median OS
was 15.4 months, and median PFS was 3.7 months [25, 26].
A Phase 3 study investigated single agent carfilzomib vs
low-dose corticosteroid and optional cyclophosphamide in
patients who had received at least three prior treatments,
including bortezomib, lenalidomide, or thalidomide, an
alkylating agent and corticosteroids, and who were refrac-
tory to their most recent therapy. The primary endpoint of
median OS was 10.2 months in the carfilzomib group
compared with 10.0 months in the control group, and
median PFS was 3.7 vs 3.3 months, respectively [27].
Isatuximab was generally well tolerated at doses ≥10 mg/
kg, with no observed dose-dependency in terms of type,
incidence, and severity of TEAEs. Few patients dis-
continued treatment due to AEs. With the administration of
prophylactic premedications, and no mandated postinfusion
corticosteroids, IRs occurred in approximately half of
patients, mostly during the first infusion, and were mild-to-
moderate in almost all cases. The duration of isatuximab
infusion could be reduced after the first infusion (to 2.6 h for
10 mg/kg and 4.4 h for 20 mg/kg), without incurring any
increased risk of IRs.
A previous study found an association between receptor
density and response to daratumumab, reflecting an
observed link between CD38 expression levels on patient
MM cells and induced cell death by daratumumab via
ADCC and CDC [28, 29]. In this study, an exploratory
analysis of CD38 receptor density did not detect any asso-
ciation with clinical response to isatuximab. Although
limited by the number of patients evaluable, these pre-
liminary findings would caution against the use of CD38
expression levels as a predictive marker of isatuximab
efficacy. Further exploration with other next-generation
CD38 monoclonal antibodies such as SAR442085 is
recommended.
Isatuximab induces both Fc-dependent and Fc-
independent pathways to kill CD38-expressing tumor cells
[12, 13]. Of these, Fc-dependent natural killer cell-mediated
ADCC is a key mechanism that occurs in both low and high
CD38-expressing tumor plasma cells [14]. The affinity of
the natural killer cell FcγRIIIA receptor to the Fc portion of
IgG antibodies is increased by a naturally occurring F to V
mutation [30]. Exploratory analyses in this study revealed a
higher ORR in patients with the high-affinity FcγRIIIA V/V
variant than patients with the lower-affinity F/F or F/V
variants. Larger studies are needed to determine
whether these findings are generalizable in a broader MM
population and whether FcγRIIIA variant status could be
predictive of response to isatuximab, including in combi-
nation therapy.
This study confirms the findings from a Phase 1 study of
single agent isatuximab in heavily pretreated patients with
RRMM (median 5 prior lines of therapy, including an IMiD
and PI), where the ORR was 24% at doses ≥10 mg/kg [15].
There was no clear dose–response relationship between 10
and 20 mg/kg. PK/pharmacodynamic modeling and simu-
lations of ORR and serum M-protein (a surrogate for tumor
growth) showed better efficacy with a deeper response in
terms of serum M-protein reduction at dose 20 mg/kg
compared with 10 mg/kg, and 20 mg/kg was subsequently
chosen as the optimal dose for single agent isatuximab [31].
This decision is supported by PK data from this study;
steady state was reached by Cycle 2 with the 20 mg/kg QW/
Q2W regimen, whereas variations in accumulation ratios for
Cmax and Ctrough between Cycle 2 and Cycle 6 were
observed with both 10 mg/kg regimens. Furthermore, PK
data from a Phase 1 study of isatuximab in patients with
RRMM or other CD38-positive hematologic malignancies
indicate that, at 10 mg/kg Q2W, Cycle 1 plasma trough
levels of isatuximab are consistently above the lowest
pharmacological active dose in mouse tumor models (10 μg/
ml), and at dose 20 mg/kg Q2W, Cycle 2 trough levels are
above the concentration needed for tumor eradication (129
μg/ml) [32]. Notably, PFS appears to drop after 4 months in
the 10 mg/kg Q2W/Q4W cohort compared with the other
highest dosing groups, suggesting that Q2W administration
after loading is important to maintain a response in patients
with advanced MM.
As patients were not randomized to the 20 mg/kg QW/
Q2W group, direct comparisons cannot be made between
this and the other study arms. It is also noteworthy that
detection of the therapeutic monoclonal antibody may
obscure whether a patient with an IgG-kappa M-spike has
attained a complete hematologic remission. A CR per
IMWG criteria requires the absence of M-protein by
immunofixation, while a VGPR allows M-protein detect-
able by immunofixation but not on electrophoresis [16, 33].
Higher interference from isatuximab at the 20 mg/kg dose
may contribute to a lower VGPR rate at this dose level
compared with lower doses. At the time the study was
conducted, there was no available assay to detect, and
therefore remove, this interference.
Part 2 of this study is ongoing to evaluate isatuximab
20 mg/kg as monotherapy or in combination with dex-
amethasone in patients with RRMM (NCT01084252). Isa-
tuximab is also being investigated in combination regimens
[34–36] and Phase 3 trials are underway; the ICARIA study
has shown that addition of isatuximab to pomalidomide-
dexamethasone improves the ORR and PFS, including in
patients with adverse characteristics such as high-risk
cytogenetics, heavy pretreatment, and renal impairment
(NCT02990338) [35, 37–40]. Other Phase 3 trials are
evaluating the addition of isatuximab to lenalidomide,
bortezomib, and dexamethasone (RVd) in patients with
newly diagnosed MM (NCT03617731 and NCT03319667),
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple. . .
and carfilzomib and dexamethasone in patients with RRMM
(NCT03275285).
In conclusion, isatuximab demonstrated single agent
activity in heavily pretreated patients with RRMM,
including high-risk patients, and these responses were more
durable at doses ≥10 mg/kg. Isatuximab was generally well
tolerated. The time burden of infusions could be safely
reduced following the first infusion and most IRs were
mild-to-moderate in severity and rarely occurred after the
first infusion. Isatuximab is a significant new treatment
option for patients with RRMM and studies are ongoing for
use both as a single agent and in combination with other
treatment regimens.
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